Inotek Pharmaceuticals is a leader in the development of innovative drug candidates to address significant diseases of the eye.

The Company's lead program, INO-8875, is a highly selective Adenosine-1 receptor agonist being evaluated for the treatment of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. The candidate has completed a Phase 1/2 clinical trial in patients and is currently being evaluated in a multiple-dose Phase 2 trial. In the Phase 1/2 study, treatment with INO-8875 was well tolerated and resulted in a statistically significant reduction in intraocular pressure (IOP).

Additionally, Inotek has a portfolio of emerging programs targeting a broad range of retinal diseases, including age-related macular degeneration.

Inotek has built a first-class drug development and management team to move the Company's programs forward in clinical trials. The Company is privately held and is based in Lexington, MA.